SCHEMBL7043650

SCHEMBL7043650

O=c1[nH]c(-c2cc(Cl)c(Cl)s2)nn1-c1cc(Cl)ccc1O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.34
ALDH1A1 P00352 2/20 0.34
TSHR P16473 2/20 0.31
HSD17B10 Q99714 2/20 0.31
CYP3A4 P08684 2/20 0.31
TDP1 Q9NUW8 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C19 P33261 1/20 0.31
ESR1 P03372 1/20 0.31
KCNMA1 Q12791 1/20 0.31
HTT P42858 2/20 0.30
HSP90AA1 P07900 1/20 0.30
KDM4E B2RXH2 1/20 0.30
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30
CDK4 P11802 1/20 0.30
CCND1 P24385 1/20 0.30
TDP2 O95551 1/20 0.30
DAO P14920 3/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7042394 0.88 IDO1 (0.33) IDO1ALDH1A1
SCHEMBL7039150 0.84 PTGS2 (0.35) IDO1ALDH1A1CYP3A4CYP1A2CYP2D6
SCHEMBL7044160 0.84 IDO1 (0.33) IDO1ALDH1A1
SCHEMBL7043609 0.83 LMNA (0.40) ALDH1A1TSHRHSD17B10TDP1HTT
SCHEMBL7039901 0.82 CNR1 (0.36) IDO1ALDH1A1CYP3A4CYP1A2CYP2D6
SCHEMBL7045380 0.82 SNCA (0.36) IDO1ALDH1A1CYP3A4CYP1A2CYP2D6
SCHEMBL7039107 0.82 IDO1 (0.35) IDO1ALDH1A1CYP3A4CYP1A2CYP2D6
SCHEMBL7043649 0.82 IDO1 (0.32) IDO1ALDH1A1HTTMEN1KMT2A
SCHEMBL7043568 0.81 MEN1 (0.36) IDO1ALDH1A1CYP3A4CYP1A2CYP2D6
SCHEMBL7044105 0.81 IDO1 (0.34) IDO1ALDH1A1CYP3A4CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6613786-B2 Treating urinary incontinence, asthma, irritable bowel syndrome or male erectile dysfunction BRISTOL-MYERS SQUIBB COMPANY 2003-09-02 US claimed
US-20030144333-A1 Thiophenyl triazol-3-one derivatives as smooth muscle relaxants HEWAWASAM PIYASENA (US) 2003-07-31 US claimed
US-6613786-B2 Treating urinary incontinence, asthma, irritable bowel syndrome or male erectile dysfunction BRISTOL-MYERS SQUIBB COMPANY 2003-09-02 US disclosed
US-20030144333-A1 Thiophenyl triazol-3-one derivatives as smooth muscle relaxants HEWAWASAM PIYASENA (US) 2003-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144333-A1 Thiophenyl triazol-3-one derivatives as smooth muscle relaxants PDE3A, ADRB2, ADRB3 IDO1 171/4885ALDH1A1 1237/4885TSHR 1867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.